Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy

Transplantation

Volumn 86, Issue 6, 2008, Pages 820-825

  Reinsmoen, Nancy L ^a   Lai, Chih Hung ^a   Vo, Ashley ^a   Cao, Kai ^a   Ong, Geraldine ^a   Naim, Mehrnoush ^a   Wang, Qi ^a   Jordan, Stanley C ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Desensitization; High dose IVIG; HLA specific antibodies; Positive crossmatch; Rituximab

Indexed keywords

ALEMTUZUMAB; CREATININE; IMMUNOGLOBULIN; RITUXIMAB; ALLOANTIBODY; ANTIBODY; HLA ANTIGEN;

ANTIBODY BLOOD LEVEL; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DESENSITIZATION; HUMAN; HUMAN TISSUE; KIDNEY DONOR; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; RISK FACTOR; T LYMPHOCYTE; BLOOD; CADAVER; DONOR; DRUG ADMINISTRATION; FLOW CYTOMETRY; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; LIVING DONOR; METHODOLOGY; PATIENT SELECTION; STATISTICS;

ANTIBODIES; CADAVER; CREATININE; DESENSITIZATION, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; FLOW CYTOMETRY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; LIVING DONORS; PATIENT SELECTION; T-LYMPHOCYTES; TISSUE DONORS;

EID: 56049093677     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181856f98     Document Type: Article

References (44)

1. The Organ Procurement and Transplantation Network; 2007. Available at: http://www.OPTN.org.
2. Jackson AM, Zachary AA. The problem of transplanting the sensitized patient: Whose problem is it? QFront Biosci 2008; 13: 1396.
3. Lee PC, Terasaki PI, Takemoto SK,et al. All chronic rejection failures of kidney transplants were precededby the development ofHLA antibodies. Transplantation 2002; 74: 1192.
4. Michaels PJ, Fishbein MC, Colvin RB. Humoral rejection of human organ transplants. Springer Semin Immunopathol 2003; 25: 119.
5. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033.
6. Reinsmoen NL, Nelson K, Zeevi A. Anti-HLA antibody analysis and crossmatching in heart and lung transplantation. Transplant Immunol 2004; 13: 63.
7. Leffell MS, Montgomery RA, Zachary AA. The changing role of antibody testing in transplantation. Clin Transpl 2005; 259.
8. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant 2004; 8: 535.
9. Zachary AA, Montgomery RA, Leffell MS. Desensitization protocols improving access and outcome in transplantation. Clin Appl Immunol 2005; 5: 373.
10. Crew RJ, Ratner LE. Overcoming immunologic incompatibility: Transplanting the difficult to transplant patient. Semin Dial 2005; 18: 474.
11. Jordan SC,VoAA, PengA,et al. Intravenous gammablobulin (IVIG): A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006; 6: 459.
12. Magee CC. Transplantation across previously incompatible immuno-logical barriers. Transpl Int 2006; 19: 87.
13. Zachary AA, Montgomery RA, Jordan S, et al. 14th international HLA and immunogenetics workshop: Report on understanding antibodies in transplantation. Tissue Antigens 2007; 69: 160.
14. Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76: 631.
15. Jordan SC, Tyan DB, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IGO2 trial. J Am Soc Nephrol 2004; 15: 3256.
16. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immunoglobulin G for desensitization in renal transplantation. N Engl J Med 2008; 359: 242.
17. Zachary AA, Montgomery RA, Leffell MS. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin.Hum Immunol 2005; 66: 364.
18. Tyan DB, Li VA, Czer L, et al. Intravenous immunoglobulinsuppres- sionofHLA alloantibodyinhighly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57: 553.
19. Bray RA, Lebeck KL, Gebel HM. The flow cytometric crossmatch: Dual color analysis of T cell and B cell reactivities. Transplantation 1989; 48: 834.
20. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
21. RotmanS, Collins AB, Colvin RB. C4d depositioninallografts: Current concepts and interpretation. Transpl Rev 2005; 19: 65.
22. Cecka JM, Zhang Q, Reed EF. Preformed cytotoxic antibodies in potential allograft recipients: Recent data. Tissue Antigens 2007; 69: 160.
23. Bray RA, Nickerson PW, Kerman RH, et al. Evolution of HLA antibody detection: Technology emulating biology. Immunol Res 2004; 29: 41.
24. Scornik JC, Clapp W, Patton PR, et al. Outcome of kidney transplants in patients known to be flow cytometry crossmatch positive. Transplantation 2001; 71: 1098.
25. Wen R, Wu V, Dmitrienko S, et al. Biomarkers in transplantation: Prospective, blinded measurement of predictive value for the flow cytometry crossmatch after negative antiglobulin crossmatch in kidney transplantation. Kidney Int 2006; 70: 1474.
26. Vasilescu ER,Ho EK, Colovai AI, et al. Alloantibodies and the outcome of cadaver kidney allografts. Hum Immunol 2006; 67: 597.
27. Vaidya S. Clinical importance of anti-human leukocyte antigen-specific antibody concentration in performing calculated panel reactive antibody and virtual crossmatches. Transplantation 2008; 85: 1046.
28. Bielmann D, Hönger G, Lutz D, et al. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant 2007; 7: 626.
29. Zangwill SD, Ellis TM, Zlotcha J, et al. The virtual crossmatch - A screening tool for sensitized pediatric hearth transplant recipients. Pediatr Transplant 2006; 10: 38.
30. Mytilineos J, Deufel A, Opelz G. Clinical relevante of HLA-DPB locus matching for cadaver kidney transplants: A report of the collaborative transplant study. Transplantation 1997; 63: 1351.
31. Goral S, Prak EL, Kearns J, et al. Preformed donor-directed anti-HLA-DP antibodies may be an impediment to successful kidney transplantation. Nephrol Dial Transplant 2008; 23: 390.
32. Vaidya S, Hilson B, Sheldon S, et al. DP reactive antibody in a zero mismatch renal transplant pair. Hum Immunol 2007; 68: 947.
33. Emery P, Mach B, Reith W. The different level of expression of HLA-DRB1 and -DRB3 genes is controlled by conserved isotypic differences in promoter sequence. Hum Immunol 1993; 38: 137.
34. Stunz LL, Karr RW, Anderson RA. HLA-DRB1 and -DRB4 genes are differentially regulated at the transcriptional level. J Immunol 1989; 143: 3081.
35. Platt JL, Vercellotti GM, Dalmasso AP, et al. Transplantation of discordant xenografts: A review of progress. Immunol Today 1990; 11: 450.
36. Koch CA, Khalpey ZI, Platt JL. Accommodation: Preventing injury in transplantation and disease. J Immunol 2004; 172: 5143.
37. Tabata T, de Perrot M, Keshavjee S, et al. Accommodation after lung xenografting from hamster to rat. Transplantation 2003; 75: 607.
38. Gloor JM, DeGoey S, Ploeger N, et al. Persistence of low levels of al-loantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 2004; 78: 221.
39. Jindra PT, Zhang X, Mulder A, et al. Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation 2006; 82: S33.
40. Narayanan K, Jaramillo A, Phelan DL, et al. Pre-exposure to sub-saturating concentrations of HLA class I antibodies confers resistance to endothelial cells against antibody complement-mediated lysis by regulating Bad through the phosphatidylinositol 3-kinase/Akt pathway. Eur J Immunol 2004; 34: 2303.
41. Jindra PT, Jin Y, Rozengurt E, et al. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol 2008; 180: 2357.
42. Jin YP, Fishbein MC, Said JW, et al. Anti-HLA class I antibody-mediated activation of the PI3K/Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells. Hum Immunol 2004; 65: 291.
43. Salama AD, Delikouras A, Pusey CD, et al. Transplant accommodation in highly sensitized patients: A potential role for Bcl-xL and alloanti-body. Am J Transplant 2001; 1: 260.
44. Narayanan K, Jendrisak MD, Phelan DL, et al. HLA class I antibody mediated accommodation of endothelial cells via the activation of PI3K/cAMP dependent PKA pathway. Transpl Immunol 2006; 15: 187.